These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2880114)

  • 21. Premenstrual depression, cortisol and oestradiol treatment.
    Crammer JL
    Psychol Med; 1986 May; 16(2):451-5. PubMed ID: 3014589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of oestrogen on the sleep, mood, and anxiety of menopausal women.
    Thomson J; Oswald I
    Br Med J; 1977 Nov; 2(6098):1317-9. PubMed ID: 338104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women.
    Salmaggi P; Bressa GM; Nicchia G; Coniglio M; La Greca P; Le Grazie C
    Psychother Psychosom; 1993; 59(1):34-40. PubMed ID: 8441793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma oestrone, oestradiol and gonadotrophin concentrations in postmenopausal patients treated with oestradiol or with a combination of oestradiol and oestriol.
    Sipinen S
    Ann Clin Res; 1979 Oct; 11(5):172-8. PubMed ID: 121048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined exercise training reduces climacteric symptoms without the additive effects of isoflavone supplementation: A clinical, controlled, randomised, double-blind study.
    Costa JG; Giolo JS; Mariano IM; Batista JP; Ribeiro ALA; Souza TCF; de Oliveira EP; Resende APM; Puga GM
    Nutr Health; 2017 Dec; 23(4):271-279. PubMed ID: 29214925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being.
    Flöter A; Nathorst-Böös J; Carlström K; von Schoultz B
    Climacteric; 2002 Dec; 5(4):357-65. PubMed ID: 12626215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women.
    Appleby L; Montgomery J
    Br Med J (Clin Res Ed); 1987 May; 294(6584):1417-8. PubMed ID: 3109683
    [No Abstract]   [Full Text] [Related]  

  • 28. [The psychiatric aspect of the climacteric syndrome: its clinical picture and treatment].
    Tiuvina NA; Balabanova VV; Balan VE; Butareva LB
    Akush Ginekol (Mosk); 1993; (4):34-7. PubMed ID: 8250115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study.
    Panay N; Al-Azzawi F; Bouchard C; Davis SR; Eden J; Lodhi I; Rees M; Rodenberg CA; Rymer J; Schwenkhagen A; Sturdee DW
    Climacteric; 2010 Apr; 13(2):121-31. PubMed ID: 20166859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study.
    Dow MG; Hart DM; Forrest CA
    Br J Obstet Gynaecol; 1983 Apr; 90(4):361-6. PubMed ID: 6682336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oestrogen therapy for the menopause.
    Studd J; Watson N; Henderson A
    Br J Psychiatry; 1990 Dec; 157():931-2. PubMed ID: 2289110
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term hormone implant therapy--hormonal and clinical effects.
    Barlow DH; Abdalla HI; Roberts AD; Al Azzawi F; Leggate I; Hart DM
    Obstet Gynecol; 1986 Mar; 67(3):321-5. PubMed ID: 3945443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depression, estrogen, and perimenopause.
    Harv Womens Health Watch; 2001 Oct; 9(2):1. PubMed ID: 11684513
    [No Abstract]   [Full Text] [Related]  

  • 34. The use of hormone implants for climacteric symptoms.
    Cardozo L; Gibb DM; Studd JW; Tuck SM; Thom MH; Cooper DJ
    Am J Obstet Gynecol; 1984 Feb; 148(3):336-7. PubMed ID: 6695979
    [No Abstract]   [Full Text] [Related]  

  • 35. Improvement of the lipid profile in post menopausal women who use estradiol and testosterone implants.
    Britto R; Araújo L; Barbosa I; Silva L
    Gynecol Endocrinol; 2012 Oct; 28(10):767-9. PubMed ID: 22397585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
    Chakravarti S; Collins WP; Thom MH; Studd JW
    Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women.
    Selby PL; Peacock M
    Br Med J (Clin Res Ed); 1986 Nov; 293(6558):1337-9. PubMed ID: 3098341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG; Clayton A; Bao W; Guico-Pabia CJ
    Menopause; 2014 Aug; 21(8):799-806. PubMed ID: 24448103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oestradiol treatment helped a depressed postmenopausal woman to stop her psychotropic medication: a case report.
    Korhonen S; Saarijärvi S
    Acta Psychiatr Scand; 1996 Dec; 94(6):480-1. PubMed ID: 9021004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The psychotropic properties of estrogens.
    Herrmann WM; Beach RC
    Pharmakopsychiatr Neuropsychopharmakol; 1978 Jul; 11(4):164-76. PubMed ID: 209485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.